
    
      Doses are increased sequentially from low-capacity groups, and within six weeks after the
      last dose of the last subject in the ongoing dose phase, if available pharmacokinetic data
      are judged acceptable under review by investigators, sponsor and safety review committees,
      then proceed to the next dose stage.
    
  